Treatment of chronic hepatitis C infection with direct acting antivirals: effects on liver fibrosis and patient reported outcomes

Recruiting

• Conditions: Hepatitis C infection; antivirals; 10019654

• Registration Number: NL-OMON42320
• Lead Sponsor: Afdeling Maag-, Darm en Leverziekten

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

- Chronic hepatitis C
- Age > 18 years
- METAVIR score F3-F4 (classified by liver biopsy or Fibroscan score >9,5 kPa)
- Status after liver transplantation or on the waiting list for liver transplantation
- Severe extra hepatic disease (HCV-related skin disease like prophyria cutanea tarda or leukocytoclastic vasculitis; or HCV related renal impairment secondary to cryoglobulinemia

Exclusion Criteria

- Patients who don't meet the criteria for DAA treatment
- Patients who are not able to visit the outpatient clinic at regular basis

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>• Liver stiffness measurements<br /><br>• Parameters of portal hypertension<br /><br>• Serum fibrosis markers<br /><br>• Patient reported outcomes</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>